Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | DHODH | Q02127 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23458451 | 0.87 | NAPRT (0.59) | NAPRTKMT2ADHODHMAPTMEN1 | |
| SCHEMBL5046047 | 0.87 | NAPRT (0.59) | NAPRTKMT2ADHODHMAPTMEN1 | |
| SCHEMBL27612856 | 0.86 | NAPRT (0.73) | NAPRTKMT2ADHODHMAPTGAA | |
| SCHEMBL29574424 | 0.80 | NAPRT (1.00) | NAPRTDHODHMAPTALDH1A1KDM4E | |
| SCHEMBL19280924 | 0.80 | NAPRT (1.00) | NAPRTDHODHMAPTALDH1A1KDM4E | |
| SCHEMBL229352 | 0.80 | NAPRT (1.00) | NAPRTDHODHMAPTALDH1A1KDM4E | |
| SCHEMBL5215099 | 0.80 | NAPRT (0.54) | NAPRTKMT2ADHODHMAPTALDH1A1 | |
| SCHEMBL5214245 | 0.80 | NAPRT (0.54) | NAPRTKMT2ADHODHMAPTALDH1A1 | |
| SCHEMBL29710001 | 0.79 | AKR1C3 (0.53) | NAPRTAKR1C3KMT2ADHODHMAPT | |
| SCHEMBL13278446 | 0.79 | AKR1C3 (0.53) | NAPRTAKR1C3KMT2ADHODHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799627-B1 | IRON OR COBALT-CATALYZED CARBON-CARBON COUPLING REACTION OF ARYLS, ALKENES AND ALKINES WITH COPPER REAGENTS | SALTIGO GMBH (DE) | 2010-05-05 | — | — | EP | disclosed |
| US-20080269514-A1 | Iron or Cobalt-Catalyzed Carbon-Carbon Coupling Reaction of Aryls, Alkenes and Alkines With Copper Reagents | SALTIGO GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269514-A1 | Iron or Cobalt-Catalyzed Carbon-Carbon Coupling Reaction of Aryls, Alkenes and Alkines With Copper Reagents | SALTIGO GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-7176215-B2 | Bicyclic oxopyridine and oxopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2007-02-13 | — | — | US | disclosed |
| US-20050020660-A1 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | UCB, S.A. (BE) | 2005-01-27 | — | — | US | disclosed |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | UCB PHARMA S.A. (BE) | 2004-12-16 | — | — | US | disclosed |
| EP-1438313-A1 | BICYCLIC OXOPYRIDINE AND OXOPYRIMIDINE DERIVATIVES | Celltech R & D Limited (GB) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003033502-A1 | BICYCLIC OXOPYRIDINE AND OXOPYRIMIDINE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-04-24 | — | — | WO | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| CN-1254335-A | Nicotinamide derivatives | PFIZER PROD INC (US) | 2000-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269514-A1 | Iron or Cobalt-Catalyzed Carbon-Carbon Coupling Reaction of Aryls, Alkenes and Alkines With Copper Reagents | SLC39A14, MAL2, AHR | NAPRT 2091/4885AKR1C3 302/4885KMT2A 467/4885 |
| US-20050020660-A1 | Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | CHRM2, CHRM3, CHRM1 | NAPRT 2804/4885AKR1C3 291/4885KMT2A 1218/4885 |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | MAPK1, ALK, NAT1 | NAPRT 987/4885AKR1C3 331/4885KMT2A 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.